ACAD
ACADIA Pharmaceuticals Inc
Price:  
24.01 
USD
Volume:  
2,446,466.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

Acadia EV/EBITDA

-154.8%
Upside

As of 2024-03-01, the EV/EBITDA ratio of ACADIA Pharmaceuticals Inc (ACAD) is -27.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acadia's latest enterprise value is 3,843.76 mil USD. Acadia's TTM EBITDA according to its financial statements is -140.66 mil USD. Dividing these 2 quantities gives us the above Acadia EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 13.1x - 17.7x 14.9x
Forward P/E multiples 16.1x - 19.7x 17.2x
Fair Price (13.20) - (14.57) (13.15)
Upside -155.0% - -160.7% -154.8%
24.01 USD
Stock Price
(13.15) USD
Fair Price

Acadia EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-03-01 -27.33
2024-02-29 -26.43
2024-02-28 -27.02
2024-02-27 -30.07
2024-02-26 -29.53
2024-02-23 -28.23
2024-02-22 -28.31
2024-02-21 -28.33
2024-02-20 -28.31
2024-02-16 -28.61
2024-02-15 -28.69
2024-02-14 -29.14
2024-02-13 -29.14
2024-02-12 -30.54
2024-02-09 -30.07
2024-02-08 -29.28
2024-02-07 -28.73
2024-02-06 -29.35
2024-02-05 -28.60
2024-02-02 -28.82
2024-02-01 -29.81
2024-01-31 -29.54
2024-01-30 -30.62
2024-01-29 -31.45
2024-01-26 -30.75
2024-01-25 -31.02
2024-01-24 -31.04
2024-01-23 -32.16
2024-01-22 -31.70
2024-01-19 -31.16
2024-01-18 -31.51
2024-01-17 -31.96
2024-01-16 -33.09
2024-01-12 -32.84
2024-01-11 -32.92
2024-01-10 -33.50
2024-01-09 -35.09
2024-01-08 -34.47
2024-01-05 -34.70
2024-01-04 -34.26
2024-01-03 -33.82
2024-01-02 -35.32
2023-12-29 -35.85
2023-12-28 -35.93
2023-12-27 -36.38
2023-12-26 -35.63
2023-12-22 -35.95
2023-12-21 -33.76
2023-12-20 -33.21
2023-12-19 -34.47